Pfizer halts Lyrica study on positive results; Gilead gains rights to Boehringer HIV drugs; Immune Design collects $11 million;

@FierceBiotech: Cougar founder snags Pfizer cancer drug, raises $55M, launches biotech (called Puma). News | Follow @FierceBiotech

@ JohnCFierce: From the WSJ: "many innovative start-up (med-tech) companies are choosing to commercialize, and hence create jobs, overseas." Really? | Follow @JohnCFierce

@RyanMFierce: Kevin Davies cool piece on DNA Electronics and it's "one chip, one drug" or "bug" vision in POC diagnostics. News | Follow @RyanMFierce

@MaureenFierce: Sanofi boosts India presence with $300M investment. Sanofi hits two birds (vaccines, emerging markets) with one stone. Item | Follow @MaureenFierce

> Pfizer has received some welcome news on the research front: A clinical trial for its blockbuster drug Lyrica proved so effective for epilepsy that researchers opted to stop the study. An added approval would give the pharma giant some much-needed added revenue. Report

> Gilead has snapped up the worldwide rights to an experimental set of HIV therapies held by Boehringer. Gilead didn't reveal the upfront or milestone payments it committed to in the deal, but gains development and commercialization rights for a new type of treatment that targets an enzyme needed in the viral replication process. Story

> Xconomy reports that Seattle-based Immune Design has collected an $11 million tranche from its latest venture round. Story

> Shares of BioCancell Therapeutics jumped after word spread that the FDA had given its BC-819 pancreatic-cancer drug fast track status. Report

> Catabasis Pharmaceuticals has begun a Phase I study of its lead drug for Type 2 diabetes. The biotech's Series A round brought in $40 million last year. Report

Pharma News

@FiercePharma: Avista sold out of Nycomed, but it's taking ex-CEO Hajan Bjorklund with it to work healthcare. Avista release | Follow @FiercePharma

> Pfizer halts epilepsy study on Lyrica efficacy. Report

> Swiss haggling yields 30% Lucentis discount. News

> Baby 'halo' saves J&J brand from recalls, legal woes. Story

Vaccines News

> Sanofi boosts India presence with $300M vaccine investment. News 

> Addiction vaccines face added funding hurdles. Story 

> Emergent BioSolutions gets gov't order for BioThrax. Item

> Study: Parents making their own vaccine schedules for children. Report

> Computer model could take kinks out of vaccine supply chain. Piece

Manufacturing News

> MIT's Hockfield reports worrisome lack of interest in manufacturing. News 

> FDA grants to boost manufacturing, regulatory science. Story 

> Baxter faces land contamination suit in PR. Article 

> Saudi Arabia continues to beckon Big Pharma. News 

> Hospital perspective of shortages casts pharma earnings in bad light. Piece

> Rep. Cummings finds drug shortage gray market prospering. Story

And Finally... The NCI expects the number of cancer survivors over the age of 65 to swell by 42% over the next decade. Release

Suggested Articles

The FDA rejected CytoDyn’s application for its lead program, a treatment for HIV because it’s missing some information.

Dewpoint Therapeutics is teaming up with Merck to develop a new way to fight HIV using its molecular condensates platform.

The study linked SPK-8011 to improvements in factor VIII expression and bleeding out to 3.3 years, but it will be 2021 before phase 3 dosing begins.